Christian S Hinrichs
Rutgers Cancer Institute · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christian S Hinrichs as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05686226 · E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersChristian Hinrichs · recruiting · Cervical Cancer, Throat Cancer, Oropharynx Cancer · principal investigator
- Ph1/Ph2NCT05639972 · E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersChristian Hinrichs · recruiting · HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy · principal investigator
- Ph1NCT05483491 · KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerChristian Hinrichs · recruiting · Gastric Cancer, Breast Cancer, Cervical Cancer · principal investigator
- N/ANCT04428918 · Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell TransplantationNational Cancer Institute (NCI) · withdrawn · Hematopoietic Stem Cell Transplantation, Cell Transplantation, Hematologic Malignancies · principal investigator
- Ph1NCT04411134 · E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial NeoplasiaNational Cancer Institute (NCI) · withdrawn · Cervical Intraepithelial Neoplasia · principal investigator
- Ph2NCT04044950 · A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal CancerNational Cancer Institute (NCI) · withdrawn · Papillomavirus Infections, Oropharyngeal Neoplasms · principal investigator
- Ph1/Ph2NCT02280811 · T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated CancersNational Cancer Institute (NCI) · completed · Vaginal Cancer, Cervical Cancer, Anal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- E7 TCR-T cell therapy for HPV-associated cancersU01CA287904 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · fiscal years 2024 to 2026 · $627,892 awarded in 2026Grant number is on one of their registry trials
- Expanding the Reach of TCR-T Therapies for HPV16-Associated Cancers Beyond HLA-A*02:01R01CA316381 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · fiscal years 2026 · $651,548 awarded in 2026Same name and institution; not confirmed by an ID
- Developing TCR-T cell therapy in renal cell carcinomaR21CA286389 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · fiscal years 2024 to 2025 · $183,494 awarded in 2025Same name and institution; not confirmed by an ID
- The Landscape of Tumor intrinsic Genetic Resistance to T cell TherapyR00CA195682 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · fiscal years 2023 to 2025 · $783,430 awarded in 2025Same name and institution; not confirmed by an ID
- T-cell receptor gene therapy for cancerZIABC011479 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2013 to 2021 · $2,022,756 awarded in 2021Same name and institution; not confirmed by an ID
- T-Cell Receptor Gene Therapy for Human Cancers-CuresZIABC011871 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 · $2,287,338 awarded in 2020Same name and institution; not confirmed by an ID
- Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancersZIABC011478 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2013 to 2017 · $934,220 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.